Ixabiso lefektri china-i-antillin rabbit polyclonal prisple ye-antibodies

Inkcazo emfutshane:


  • Ixesha lovavanyo:Imizuzu eli-10-15
  • Ixesha elifanelekileyo:Inyanga engama-24
  • I-Accuranity:Ngaphezulu kwe-99%
  • Ukucaciswa:I-1/6 yovavanyo / ibhokisi
  • Iqondo lokugcina:2 ℃ -30 ℃
  • :
  • Iinkcukacha zemveliso

    Iimpawu zeMveliso

    Sithatha "unobuhlobo bomthengi, ojolise kumgangatho, ohlanganisiweyo, obonakalayo" njengeenjongo. "Inyaniso nethembekileyo" Ngaba ukulawulwa kwethu kufanelekile kwixabiso lefektri i-anti-rabbin rabbit polyclonIi-antibodies eziphambili, Siya kubamkela ngentliziyo iphela bonke abathengi kwishishini ababini ekhaya nakwamanye amazwe ukuba basebenzisane ngesandla, kwaye bavelise ikamva eliqaqambileyo.
    Sithatha "unobuhlobo bomthengi, ojolise kumgangatho, ohlanganisiweyo, obonakalayo" njengeenjongo. "Inyaniso nethembekileyo" lulawulo lwethu olulungileyoI-China iAntis, Ii-antibodies eziphambili, Iqela lethu lezobunjineli eliqeqeshiweyo liza kukulungele ukukhonza ngokubonisana nengxelo. Sikwazile ukukuphelisa simahla kwiisampulu zokuhlawula iimfuno zakho. Eyona mizamo iya kuveliswa kuku kukuhambisa eyona nkonzo kunye nentengiso. Xa unomdla kwishishini lethu kunye neemveliso, kufuneka uthethe kuthi ngokusithumela i-imeyile okanye usitsalele ngokukhawuleza. Kwimizamo yokwazi iimveliso zethu kunye nenkampani eyongezelelweyo, unokuza kumzi-mveliso wethu ukuyijonga. Ngokuqhelekileyo siya kuzimkela iindwendwe ezivela kwihlabathi liphela kwishishini lethu ukudala ubudlelwane kunye nathi. Nceda uzive uneendleko zokuthetha kuthi ngeshishini elincinci kwaye siyakholelwa ukuba siza kwabelana nabanye ngamava orhwebo awona mveliso wonke.
    I-cea

    cal_conew1

     

    Iimveliso Inkcazo ikhowudi iyunithi Uluhlu lwelayini Uluhlu lwereferensi Uluhlu lwelayini
    Ikhithi yokufumana isifo se-carcinotic antign I-25t / ibhokisi I-cea Ng / ml 2-500 <5

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


  • Ngaphambili:
  • Okulandelayo: